Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning balance at Dec. 31, 2020 $ 43 $ 46,366 $ (90,180) $ (43,771)
Beginning balance (in shares) at Dec. 31, 2020 42,973,462      
Common stock issued   6,927   6,927
Common stock issued (in shares) 333,121      
Proceeds from issuance of common stock for exercise of warrant $ 1 7,499   7,500
Proceeds from issuance of common stock for exercise of warrant (in shares) 1,496,216      
Reclassification of settlement liability upon issuance of warrant   60,852   60,852
Stock-based compensation   372   372
Net loss     (25,489) (25,489)
Ending balance at Mar. 31, 2021 $ 44 122,016 (115,669) 6,391
Ending balance (in shares) at Mar. 31, 2021 44,802,799      
Beginning balance at Dec. 31, 2021 $ 59 203,990 (183,243) 20,806
Beginning balance (in shares) at Dec. 31, 2021 58,810,550      
Common stock and warrants issued in private placement, net of issuance costs $ 8 22,972   $ 22,980
Common stock and warrants issued in private placement, net of issuance costs (in shares) 7,824,727     7,824,727
Common stock issued for consulting services   17   $ 17
Common stock issued for consulting services (in shares) 6,037      
Stock-based compensation   1,334   1,334
Net loss     (13,448) (13,448)
Ending balance at Mar. 31, 2022 $ 67 $ 228,313 $ (196,691) $ 31,689
Ending balance (in shares) at Mar. 31, 2022 66,641,314